Actos trial opens with accusations that Takeda hid cancer risks; Actelion says profits may return earlier than expected;

@FiercePharma: Branded drug companies deny samples to would-be generics makers. How? REMS, partly. Article | Follow @FiercePharma

@EricPFierce: Merck starts up $120 million China packaging plant but cuts manufacturing operations elsewhere. Story | Follow @EricPFierce

> Takeda Pharmaceutical knew about the possible cancer risks of its diabetes drug Actos 7 years before reporting data to regulators, a lawyer said during the first day of a bellwether trial over the drug. Report

> Swiss biotech Actelion ($ATLN) says it may get back into the black sooner than it had expected after sales of its flagship drug Tracleer beat expectations in the first quarter. Report

> Allergan ($AGN) lost out on FDA approval for Levadex, its inhalable version of a 60-year-old migraine treatment. Report

> Two investors snapped up Pfizer's ($PFE) former research facility in Plattsburgh, NY, with plans to move a Texas manufacturing operation there. Report

> Nestle made a deal with Mexican regulators to approve its acquisition of Pfizer's nutrition business there. Report

Medical Device News

@FierceMedDev: At long last, Sony and Olympus launch medical device joint venture. News | Follow @FierceMedDev

@MarkHFierce: The tech behind your old DVD player may have a second life as an HIV Dx tool. Story | Follow @MarkHFierce

 @DamianFierce: JNJ CFO says company still "going through the process" of deciding whether to sell/spinoff diagnostics business. | Follow @DamianFierce

> Synthes buy props up weak device sales for J&J. Report

> Panasonic to sell stake in healthcare division. Item

> Is $13.6 Billion too steep for Life Tech? More

> Supreme Court questions validity of Myriad's gene patents. Article

Biotech News

@FierceBiotech: Analysis: 2012 life sciences VC fundraising and new bets shrivel. Article | Follow @FierceBiotech

@RyanMFierce: Eli Lilly reports positive top-line results from 2 PhIIIs of GLP1 drug, but are they positive enough to rival others? Release | Follow @RyanMFierce

> Johnson & Johnson tops pharma rivals in 10-year test of R&D productivity. Report

> Sarepta slips as FDA seeks more data on eteplirsen. News

> Judge turns down motion to appoint examiner or trustee in Biovest bankruptcy case. Report

Pharma Manufacturing News

> U.S. contract manufacturers kick off expansions. Article

> Hospira again names an exec to get manufacturing in order. News

> Bristol-Myers Squibb marries early-stage processes to biologics manufacturing. Article

Biotech Research News

@EmilyMFierce: Is the World's Top Neuroscience Group Quashing Dissent on the U.S. BRAIN Initiative? More | Follow @EmilyMFierce

> Scientists develop technique to rebuild brain cells destroyed by MS, cerebral palsy. Report

> Mersana's cancer drug technology cures tumors in mice at low doses. Story

> New rat model could help scientists better understand, treat Alzheimer's. Article

> Role of brain enzyme linked to neurodegeneration in mice. Item

And Finally... Sanofi ($SNY) fires surprise torpedo at Alzheimer's drug research. Report

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.